1 |
ClinicalTrials.gov (NCT02563522) Safety and Efficacy Study of VM202 in the Treatment of Chronic Non-Healing Foot Ulcers. U.S. National Institutes of Health.
|
2 |
ClinicalTrials.gov (NCT02427464) Phase 3 Gene Therapy for Painful Diabetic Neuropathy. U.S. National Institutes of Health.
|
3 |
ClinicalTrials.gov (NCT02039401) Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis. U.S. National Institutes of Health.
|
4 |
Clinical pipeline report, company report or official report of ViroMed.
|
5 |
Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63.
|
6 |
Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury. Kidney Int Rep. 2020 Sep 25;5(12):2325-2332.
|
7 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
8 |
Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010 Sep;17(9):1152-61.
|
9 |
Targeting MET in cancer: rationale and progress.Nat Rev Cancer.2012 Jan 24;12(2):89-103.
|
10 |
Clinical pipeline report, company report or official report of Amgen (2009).
|
11 |
How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
|
|
|
|
|
|
|